With its FDA approval, JenaValve intends to commence launch activity for the Trilogy System immediately with participating clinical study sites.
CE Marked and 510(k) pending, Philips says Rembra’s advanced image reconstruction technology delivers up to 106 images per second and a high throughput of up to 270 patients per day [2] to support faster diagnosis by making scans available in near-real time.
RadNet leadership says the acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth through customer-centric innovation and disciplined capital allocation.
Cloud-based SaMD (Software as a Medical Device) designed to assist healthcare providers in predicting delivery date using ultrasound imaging
Abbott’s CardioMEMS™ HERO is a compact remote reader that is 60% lighter compared to its previous generation device for heart failure patients with Abbott’s CardioMEMS pulmonary artery pressure sensor.
The Revello™ Vascular Covered Stent is designed to combine the flexibility of a nitinol self-expanding stent with the radial resistive force tailored for the iliac arteries. Iliac artery disease is a key component in lower‑extremity peripheral artery disease (PAD), and according to a company Press Release, Revello™ can help reduce a substantial disability burden across the EU’s aging population.
Biotronik has received U.S. Food and Drug Administration (FDA) approval for its Solia CSP S pacing lead, growing access to a solution for Left Bundle Branch Area Pacing (LBBAP).
New patient-specific solution expands Catalyst’s portfolio, enabling precise translation of 3D surgical plans into the operating room to reduce steps and increase accuracy .
Trauma and Extremities partnership aligns disciplined approach to portfolio optimization and focuses on delivering long-term value for surgeons and patients
Quantum Surgical and NeuWave Medical, Inc. – both of which share an extensive focus on innovation to improve cancer patients’ outcomes – will operate as subsidiaries of Precision IO Group Inc., the newly created parent company led by medtech veteran Kurt Azarbarzin, who was recently appointed CEO.